Macrophage-derived apoESendaisuppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice

Journal of Lipid Research

Volumn 55, Issue 10, 2014, Pages 2073-2081

  Tavori, Hagai ^a,b   Fan, Daping ^c   Giunzioni, Ilaria ^a   Zhu, Lin ^b   Linton, MacRae F ^b   Fogo, Agnes B ^b   Fazio, Sergio ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein ESendai; Lipoprotein glomerulopathy; Macrophage

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; CHOLESTEROL; GREEN FLUORESCENT PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN E SENDAI; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN E;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA VALVE DISEASE; AORTITIS; ARTICLE; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; GENETIC TRANSFECTION; GLOMERULOPATHY; HYPERLIPIDEMIA; LIPID STORAGE; LIPOPROTEIN GLOMERULOPATHY; MACROPHAGE; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; BIOSYNTHESIS; GENETICS; INFLAMMATION; KIDNEY DISEASE; KNOCKOUT MOUSE; MESANGIUM; METABOLISM; PATHOLOGY;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; GLOMERULAR MESANGIUM; HYPERLIPIDEMIAS; INFLAMMATION; KIDNEY DISEASES; MACROPHAGES; MICE; MICE, KNOCKOUT; RECEPTORS, LDL;

EID: 84907494683     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M049874     Document Type: Article

References (56)

1. Eichner, J. E., S. T. Dunn, G. Perveen, D. M. Thompson, K. E. Stewart, and B. C. Stroehla. 2002. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 155: 487-495.
2. Linton, M. F., and S. Fazio. 1999. Macrophages, lipoprotein metabolism, and atherosclerosis: insights from murine bone marrow transplantation studies. Curr. Opin. Lipidol. 10: 97-105.
3. Mahley, R. W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240: 622-630.
4. Mahley, R. W., and S. C. Rall, Jr. 2000. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1: 507-537.
5. Corder, E. H., A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, A. D. Roses, J. L. Haines, and M. A. Pericak-Vance. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261: 921-923.
6. Mahley, R. W., Y. Huang, and S. C. Rall, Jr. 1999. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J. Lipid Res. 40: 1933-1949.
7. Mahley, R. W., K. H. Weisgraber, and Y. Huang. 2009. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J. Lipid Res. 50 (Suppl): S183-S188.
8. Weisgraber, K. H., and L. H. Shinto. 1991. Identification of the disulfide-linked homodimer of apolipoprotein E3 in plasma. Impact on receptor binding activity. J. Biol. Chem. 266: 12029-12034.
9. Fan, D., S. Qiu, C. D. Overton, P. G. Yancey, L. L. Swift, W. G. Jerome, M. F. Linton, and S. Fazio. 2007. Impaired secretion of apolipoprotein E2 from macrophages. J. Biol. Chem. 282: 13746-13753.
10. Linton, M. F., R. Gish, S. T. Hubl, E. Butler, C. Esquivel, W. I. Bry, J. K. Boyles, M. R. Wardell, and S. G. Young. 1991. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88: 270-281.
11. Linton, M. F., J. B. Atkinson, and S. Fazio. 1995. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 267: 1034-1037.
12. Bellosta, S., R. W. Mahley, D. A. Sanan, J. Murata, D. L. Newland, J. M. Taylor, and R. E. Pitas. 1995. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J. Clin. Invest. 96: 2170-2179.
13. Hasty, A. H., M. F. Linton, S. J. Brandt, V. R. Babaev, L. A. Gleaves, and S. Fazio. 1999. Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation. Circulation. 99: 2571-2576.
14. Yoshida, H., A. H. Hasty, A. S. Major, H. Ishiguro, Y. R. Su, L. A. Gleaves, V. R. Babaev, M. F. Linton, and S. Fazio. 2001. Isoform-specific effects of apolipoprotein E on atherogenesis: gene transduction studies in mice. Circulation. 104: 2820-2825.
15. Fazio, S., V. R. Babaev, M. E. Burleigh, A. S. Major, A. H. Hasty, and M. F. Linton. 2002. Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice. J. Lipid Res. 43: 1602-1609.
16. Yancey, P. G., Y. Ding, D. Fan, J. L. Blakemore, Y. Zhang, L. Ding, J. Zhang, M. F. Linton, and S. Fazio. 2011. Low-density lipoprotein receptor-related protein 1 prevents early atherosclerosis by limiting lesional apoptosis and inflammatory Ly-6Chigh monocytosis: evidence that the effects are not apolipoprotein E dependent. Circulation. 124: 454-464.
17. Murphy, A. J., M. Akhtari, S. Tolani, T. Pagler, N. Bijl, C. L. Kuo, M. Wang, M. Sanson, S. Abramowicz, C. Welch, et al. 2011. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J. Clin. Invest. 121: 4138-4149.
18. Wang, M., M. Subramanian, S. Abramowicz, A. J. Murphy, A. Gonen, J. Witztum, C. Welch, I. Tabas, M. Westerterp, and A. R. Tall. 2014. Interleukin-3/granulocyte macrophage colony-stimulating factor receptor promotes stem cell expansion, monocytosis, and atheroma macrophage burden in mice with hematopoietic ApoE deficiency. Arterioscler. Thromb. Vasc. Biol. 34: 976-984.
19. Khallou-Laschet, J., A. Varthaman, G. Fornasa, C. Compain, A. T. Gaston, M. Clement, M. Dussiot, O. Levillain, S. Graff-Dubois, A. Nicoletti, et al. 2010. Macrophage plasticity in experimental atherosclerosis. PLoS ONE. 5: e8852.
20. Saito, T. 1997. Abnormal lipid metabolism and renal disorders. Tohoku J. Exp. Med. 181: 321-337.
21. Andrews, P. A., P. J. O'Donnell, S. A. Dilly, S. A. Snowden, and M. Bewick. 1997. Recurrence of lipoprotein glomerulopathy after renal transplantation. Nephrol. Dial. Transplant. 12: 2442-2444.
22. Tsimihodimos, V., and M. Elisaf. 2011. Lipoprotein glomerulopathy. Curr. Opin. Lipidol. 22: 262-269.
23. Saito, T., S. Oikawa, H. Sato, and J. Sasaki. 1999. Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants. Nephron. 83: 193-201.
24. Saito, T., A. Matsunaga, and S. Oikawa. 2006. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am. J. Kidney Dis. 47: 199-211.
25. Saito, T., S. Oikawa, H. Sato, T. Sato, S. Ito, and J. Sasaki. 1999. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features. Kidney Int. Suppl. 71: S37-S41.
26. Hu, Z., S. Huang, Y. Wu, Y. Liu, X. Liu, D. Su, Y. Tao, P. Fu, X. Zhang, Z. Peng, et al. 2014. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. Kidney Int. 85: 416-424.
27. Hamatani, H., K. Hiromura, K. Kobatake, H. Yoshida, S. Kobayashi, N. Yoneda, K. Kayakabe, T. Matsumoto, T. Kuroiwa, K. Ueki, et al. 2010. Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol. Clin. Exp. Nephrol. 14: 619-624.
28. Matsunaga, A., M. Furuyama, T. Hashimoto, K. Toyoda, D. Ogino, and K. Hayasaka. 2009. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin. Exp. Nephrol. 13: 659-662.
29. Ishibashi, S., J. Herz, N. Maeda, J. L. Goldstein, and M. S. Brown. 1994. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc. Natl. Acad. Sci. USA. 91: 4431-4435.
30. Ishigaki, Y., S. Oikawa, T. Suzuki, S. Usui, K. Magoori, D. H. Kim, H. Suzuki, J. Sasaki, H. Sasano, M. Okazaki, et al. 2000. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J. Biol. Chem. 275: 31269-31273.
31. Matsunaga, A., J. Sasaki, T. Komatsu, K. Kanatsu, E. Tsuji, K. Moriyama, T. Koga, K. Arakawa, S. Oikawa, T. Saito, et al. 1999. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int. 56: 421-427.
32. Oikawa, S., A. Matsunaga, T. Saito, H. Sato, T. Seki, K. Hoshi, K. Hayasaka, H. Kotake, H. Midorikawa, A. Sekikawa, et al. 1997. Sendai (arginine 145→proline): a new variant associated with lipoprotein glomerulopathy. J. Am. Soc. Nephrol. 8: 820-823.
33. Saito, T., Y. Ishigaki, S. Oikawa, and T. T. Yamamoto. 2002. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy. Trends Cardiovasc. Med. 12: 67-70.
34. Hoffmann, M., H. Scharnagl, E. Panagiotou, W. Banghard, H. Wieland, and W. Marz. 2001. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J. Am. Soc. Nephrol. 12: 524-530.
35. Yamamoto, S., P. G. Yancey, Y. Zuo, L. J. Ma, R. Kaseda, A. B. Fogo, I. Ichikawa, M. F. Linton, S. Fazio, and V. Kon. 2011. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 31: 2856-2864.
36. Zuo, Y., P. Yancey, I. Castro, W. N. Khan, M. Motojima, I. Ichikawa, A. B. Fogo, M. F. Linton, S. Fazio, and V. Kon. 2009. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler. Thromb. Vasc. Biol. 29: 1277-1282. [Erratum. 2009. Arterioscler. Thromb. Vasc. Biol. 29: e133.]
37. Linton, M. F., A. H. Hasty, V. R. Babaev, and S. Fazio. 1998. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J. Clin. Invest. 101: 1726-1736.
38. Tavori, H., D. Fan, J. L. Blakemore, P. G. Yancey, L. Ding, M. F. Linton, and S. Fazio. 2013. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 127: 2403-2413.
39. Paigen, B., D. Mitchell, K. Reue, A. Morrow, A. J. Lusis, and R. C. LeBoeuf. 1987. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc. Natl. Acad. Sci. USA. 84: 3763-3767.
40. Ishimura, A., M. Watanabe, H. Nakashima, K. Ito, K. Miyake, S. Mochizuki, Y. Ishigaki, and T. Saito. 2009. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice. Clin. Exp. Nephrol. 13: 430-437.
41. Wen, M., S. Segerer, M. Dantas, P. A. Brown, K. L. Hudkins, T. Goodpaster, E. Kirk, R. C. LeBoeuf, and C. E. Alpers. 2002. Renal injury in apolipoprotein E-deficient mice. Lab. Invest. 82: 999-1006.
42. Langheinrich, A. C., M. Kampschulte, F. Scheiter, C. Dierkes, P. Stieger, R. M. Bohle, and W. Weidner. 2010. Atherosclerosis, inflammation and lipoprotein glomerulopathy in kidneys of apoE-/-/LDL-/- double knockout mice. BMC Nephrol. 11: 18.
43. Fazio, S., V. R. Babaev, A. B. Murray, A. H. Hasty, K. J. Carter, L. A. Gleaves, J. B. Atkinson, and M. F. Linton. 1997. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc. Natl. Acad. Sci. USA. 94: 4647-4652.
44. Moore, K. J., F. J. Sheedy, and E. A. Fisher. 2013. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 13: 709-721.
45. McGettrick, A. F., and L. A. O'Neill. 2013. How metabolism generates signals during innate immunity and inflammation. J. Biol. Chem. 288: 22893-22898.
46. Qian, Y., E. Feldman, S. Pennathur, M. Kretzler, and F. C. Brosius 3rd. 2008. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes. 57: 1439-1445.
47. Vaziri, N. D., and K. Norris. 2011. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 31: 189-196.
48. Kon, V., M. F. Linton, and S. Fazio. 2011. Atherosclerosis in chronic kidney disease: the role of macrophages. Nat. Rev. Nephrol. 7: 45-54.
49. Prieur, X., T. Roszer, and M. Ricote. 2010. Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome. Biochim. Biophys. Acta. 1801: 327-337.
50. Schiffrin, E. L., M. L. Lipman, and J. F. Mann. 2007. Chronic kidney disease: effects on the cardiovascular system. Circulation. 116: 85-97.
51. Yancey, P. G., J. Blakemore, L. Ding, D. Fan, C. D. Overton, Y. Zhang, M. F. Linton, and S. Fazio. 2010. Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. Arterioscler. Thromb. Vasc. Biol. 30: 787-795.
52. May, P. 2013. The low-density lipoprotein receptor-related protein 1 in inflammation. Curr. Opin. Lipidol. 24: 134-137.
53. Overton, C. D., P. G. Yancey, A. S. Major, M. F. Linton, and S. Fazio. 2007. Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse. Circ. Res. 100: 670-677.
54. Meyrier, A., F. Dairou, P. Callard, and B. Mougenot. 1995. Lipoprotein glomerulopathy: first case in a white European. Nephrol. Dial. Transplant. 10: 546-549.
55. Pasquariello, A., G. Pasquariello, M. Innocenti, F. Minnei, N. Funel, P. Lorusso, and G. Barsotti. 2011. Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. J. Nephrol. 24: 381-385.
56. Mourad, G., J. P. Cristol, C. Turc-Baron, and A. Djamali. 1997. Lipoprotein glomerulopathy: a new apolipoprotein-E-related disease that recurs after renal transplantation. Transplant. Proc. 29: 2376.